155
Participants
Start Date
January 20, 2020
Primary Completion Date
January 3, 2024
Study Completion Date
January 1, 2027
Acalabrutinib
acalabrutinib 100 mg twice daily orally
Rituximab
Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
Chlorambucil
Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
Research Site, Taichung
Research Site, Chiayi City
Research Site, Tainan City
Research Site, Kaohsiung City
Research Site, Manila
Research Site, Quezon City
Research Site, Makati
Research Site, Baguio City
Research Site, Cebu
Research Site, Davao City
Research Site, Taipei
Research Site, Bangkok
Research Site, Bangkok
Research Site, Bangkok
Research Site, Taipei
Research Site, Khon Kaen
Research Site, Taichung
Research Site, Chiang Mai
Research Site, Hat Yai
Research Site, Hualien City
Research Site, Hanoi
Research Site, Beijing
Research Site, Shenyang
Research Site, Qingdao
Research Site, Changchun
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Suzhou
Research Site, Xuzhou
Research Site, Hefei
Research Site, Hefei
Research Site, Changzhou
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Nanchang
Research Site, Changsha
Research Site, Zhengzhou
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guiyang
Research Site, Ho Chi Minh City
Research Site, Shijiazhuang
Research Site, Taiyuan
Lead Sponsor
AstraZeneca
INDUSTRY